Not Yet RecruitingNot Applicable

ApoE Genotyping Analysis in Patients with Suspected Non-haemorrhagic Amyloid Angiopathy

100 participantsStarted 2025-02-01

Plain-language summary

Ischaemic microangiopathic features have recently been incorporated into the criteria for cerebral amyloid angiopathy (CAA). ApoE genotyping (presence of the E4 allele) is routinely used to help determine the aetiology of a haemorrhagic microangiopathy found on MRI. Chronic ischaemic disease in CAA is characterised by the presence of : * multispot pattern on the FLAIR sequence * severe periventricular FLAIR hypersignals with posterior predominance The main aim of this study was therefore to analyse the frequency of the presence of one (or two) E4 allele(s) on ApoE genotyping in patients with suspected CAA based on ischaemic MRI involvement with a typical radiological pattern.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with ischaemic stroke (from causes other than CAA, as CAA is not a frequent cause of ischaemic stroke) with associated stigmata of microangiopathy on MRI that may suggest associated CAA. * Patients treated at Nîmes University Hospital Exclusion Criteria: * Patient refusing to participate

What they're measuring

ApoE genotypage

Timeframe: baseline

Trial details

NCT IDNCT06809062

SponsorCentre Hospitalier Universitaire de Nīmes

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-31

Contact for this trial

Dimitri RENARD, MD

(+33) 04.66.68.32.61 dimitri.renard@chu-nimes.fr

View on ClinicalTrials.gov More Amyloid Angiopathy trials